keyword
MENU ▼
Read by QxMD icon Read
search

small call lung cancer

keyword
https://www.readbyqxmd.com/read/29329590/frequent-overexpression-of-amap1-an-arf6-effector-in-cell-invasion-is-characteristic-of-the-mmtv-pymt-rather-than-the-mmtv-neu-human-breast-cancer-model
#1
Yutaro Otsuka, Tsukasa Oikawa, Hinako Yoshino, Shigeru Hashimoto, Haruka Handa, Hiroki Yamamoto, Ari Hashimoto, Hisataka Sabe
BACKGROUND: The small GTPase Arf6 and its downstream effector AMAP1 (also called ASAP1/DDEF1) constitute a signaling pathway promoting cell invasion, in which AMAP1 interacts with several different proteins, including PRKD2, EPB41L5, paxillin, and cortactin. Components of this pathway are often overexpressed in human breast cancer cells, to be correlated with poor prognosis of the patients, whereas overexpression of the Arf6 pathway did not correlate with the four main molecular classes of human breast tumors...
January 5, 2018: Cell Communication and Signaling: CCS
https://www.readbyqxmd.com/read/29324212/managing-patients-with-oligometastatic-non-small-cell-lung-cancer
#2
Sarah Jo Stephens, Michael J Moravan, Joseph K Salama
Metastatic lung cancer has long been considered incurable, with the goal of treatment being palliation. However, a clinically meaningful number of these patients with limited metastases (approximately 25%) are living long term after definitive treatment to all sites of active disease. These patients with so-called oligometastatic disease likely represent a distinct clinical group who may possess a more indolent biology compared with their more widely metastatic counterparts. Hellman and Weichselbaum proposed the existence of the oligometastatic state, on the basis of the spectrum theory of cancer spread...
January 2018: Journal of Oncology Practice
https://www.readbyqxmd.com/read/29301485/strategies-for-identification-of-somatic-variants-using-the-ion-torrent-deep-targeted-sequencing-platform
#3
Aditya Deshpande, Wenhua Lang, Tina McDowell, Smruthy Sivakumar, Jiexin Zhang, Jing Wang, F Anthony San Lucas, Jerry Fowler, Humam Kadara, Paul Scheet
BACKGROUND: 'Next-generation' (NGS) sequencing has wide application in medical genetics, including the detection of somatic variation in cancer. The Ion Torrent-based (IONT) platform is among NGS technologies employed in clinical, research and diagnostic settings. However, identifying mutations from IONT deep sequencing with high confidence has remained a challenge. We compared various computational variant-calling methods to derive a variant identification pipeline that may improve the molecular diagnostic and research utility of IONT...
January 4, 2018: BMC Bioinformatics
https://www.readbyqxmd.com/read/29299146/targeting-chaperonin-containing-tcp1-cct-as-a-molecular-therapeutic-for-small-cell-lung-cancer
#4
Ana C Carr, Amr S Khaled, Rania Bassiouni, Orielyz Flores, Daniel Nierenberg, Hammad Bhatti, Priya Vishnubhotla, J Perez Manuel, Santimukul Santra, Annette R Khaled
Identifying new druggable targets is desired to meet the needs for effective cancer treatments. To this end, we previously reported the efficacy of a therapeutic peptide called CT20p that displays selective cytotoxicity through inhibition of a multi-subunit, protein-folding complex called Chaperonin-Containing TCP-1 (CCT). To investigate the role of CCT in cancer progression, we examined protein levels of CCT subunits in liver, prostate, and lung cancer using human tissue microarrays. We found that these cancers expressed higher levels of CCT2 as compared to normal tissues...
December 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/29299121/klf15-promotes-the-proliferation-and-metastasis-of-lung-adenocarcinoma-cells-and-has-potential-as-a-cancer-prognostic-marker
#5
Lihua Gao, Hongmei Qiu, Jian Liu, Yuzhen Ma, Jia Feng, Li Qian, Jianguo Zhang, Yifei Liu, Tingting Bian
Lung adenocarcinoma (LADC)is a general form of non-small cell lung cancer that represents a significant threat to public health worldwide. The 5-year-survival rate for LADC is currently below 15%. The transcription factor KLF15, also called kidney-enriched KLF (KKLF), has been proven to play a role in inhibiting proliferation and diversification of carcinoma cells, including those of the endometrium, pancreas and breast, but the involvement of KLF15 in LADC has not previously been studied. In this study, we compared the in vitro expression of KLF15 in human LADC tissues and adjacent normal lung tissues...
December 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/29297278/incorporating-biological-prior-knowledge-for-bayesian-learning-via-maximal-knowledge-driven-information-priors
#6
Shahin Boluki, Mohammad Shahrokh Esfahani, Xiaoning Qian, Edward R Dougherty
BACKGROUND: Phenotypic classification is problematic because small samples are ubiquitous; and, for these, use of prior knowledge is critical. If knowledge concerning the feature-label distribution - for instance, genetic pathways - is available, then it can be used in learning. Optimal Bayesian classification provides optimal classification under model uncertainty. It differs from classical Bayesian methods in which a classification model is assumed and prior distributions are placed on model parameters...
December 28, 2017: BMC Bioinformatics
https://www.readbyqxmd.com/read/29290265/correlation-between-immune-related-adverse-events-and-efficacy-in-non-small-cell-lung-cancer-treated-with-nivolumab
#7
Koichi Sato, Hiroaki Akamatsu, Eriko Murakami, Seigo Sasaki, Kuninobu Kanai, Atsushi Hayata, Nahomi Tokudome, Keiichiro Akamatsu, Yasuhiro Koh, Hiroki Ueda, Masanori Nakanishi, Nobuyuki Yamamoto
OBJECTIVES: Patients treated with nivolumab often experience its unique adverse events, called immune-related adverse events (irAEs). Regarding the mechanisms of immune-checkpoint inhibitors (ICIs), the occurrence of irAEs may also reflect antitumor responses. Here, we report the clinical correlation between irAEs and efficacy in NSCLC patients treated with nivolumab. MATERIALS AND METHODS: Between December 2015 and February 2017, 38 advanced NSCLC patients were treated in our institution...
January 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29284478/phoyunnanin-e-inhibits-migration-of-non-small-cell-lung-cancer-cells-via-suppression-of-epithelial-to-mesenchymal-transition-and-integrin-%C3%AE-v-and-integrin-%C3%AE-3
#8
Nareerat Petpiroon, Boonchoo Sritularak, Pithi Chanvorachote
BACKGROUND: The conversion of the epithelial phenotype of cancer cells into cells with a mesenchymal phenotype-so-called epithelial-mesenchymal transition (EMT)-has been shown to enhance the capacity of the cells to disseminate throughout the body. EMT is therefore becoming a potential target for anti-cancer drug discovery. Here, we showed that phoyunnanin E, a compound isolated from Dendrobium venustum, possesses anti-migration activity and addressed its mechanism of action. METHODS: The cytotoxic and proliferative effects of phoyunnanin E on human non-small cell lung cancer-derived H460, H292, and A549 cells and human keratinocyte HaCaT cells were investigated by MTT assay...
December 29, 2017: BMC Complementary and Alternative Medicine
https://www.readbyqxmd.com/read/29180617/transcribed-ultraconserved-region-339-promotes-carcinogenesis-by-modulating-tumor-suppressor-micrornas
#9
Ivan Vannini, Petra M Wise, Kishore B Challagundla, Meropi Plousiou, Mirco Raffini, Erika Bandini, Francesca Fanini, Giorgia Paliaga, Melissa Crawford, Manuela Ferracin, Cristina Ivan, Linda Fabris, Ramana V Davuluri, Zhiyi Guo, Maria Angelica Cortez, Xinna Zhang, Lu Chen, Shuxing Zhang, Cecilia Fernandez-Cymering, Leng Han, Silvia Carloni, Samanta Salvi, Hui Ling, Mariam Murtadha, Paolo Neviani, Barbara J Gitlitz, Ite A Laird-Offringa, Patrick Nana-Sinkam, Massimo Negrini, Han Liang, Dino Amadori, Amelia Cimmino, Muller Fabbri, George A Calin
The transcribed ultraconserved regions (T-UCRs) encode long non-coding RNAs implicated in human carcinogenesis. Their mechanisms of action and the factors regulating their expression in cancers are poorly understood. Here we show that high expression of uc.339 correlates with lower survival in 210 non-small cell lung cancer (NSCLC) patients. We provide evidence from cell lines and primary samples that TP53 directly regulates uc.339. We find that transcribed uc.339 is upregulated in archival NSCLC samples, functioning as a decoy RNA for miR-339-3p, -663b-3p, and -95-5p...
November 27, 2017: Nature Communications
https://www.readbyqxmd.com/read/29178133/variants-with-a-low-allele-frequency-detected-in-genomic-dna-affect-the-accuracy-of-mutation-detection-in-cell-free-dna-by-next-generation-sequencing
#10
Jacqueline F Wang, Xingxiang Pu, Xiaoshan Zhang, Ken Chen, Yuanxin Xi, Jing Wang, Xizeng Mao, Jianhua Zhang, John V Heymach, Mara B Antonoff, Wayne L Hofstetter, Reza J Mehran, David C Rice, Jack A Roth, Boris Sepesi, Stephen G Swisher, Ara A Vaporciyan, Garrett L Walsh, Qing H Meng, Kenna R Shaw, Agda Karina Eterovic, Bingliang Fang
BACKGROUND: Next-generation sequencing of cell-free DNA (cfDNA) has been shown to be a useful noninvasive test for detecting mutations in solid tumors. METHODS: Targeted gene sequencing was performed with a panel of 263 cancer-related genes for cfDNA and genomic DNA of peripheral blood mononuclear cells (PBMCs) obtained from presurgical specimens of 6 lung cancer patients, and mutation calls in these samples were compared with those of primary tumors and corresponding patient-derived xenografts (PDXs)...
November 27, 2017: Cancer
https://www.readbyqxmd.com/read/29167111/hla-loss-in-nsclc-facilitating-immune-escape
#11
(no author information available yet)
Researchers have developed a new software tool, called LOHHLA, which can pinpoint allele-specific HLA loss in tumors. When applied to a cohort of patients with non-small cell lung cancer, this genomic event was detected in 40% of cases, increasing in frequency as the disease spread to the brain.
November 22, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/29103030/mir-30a-5p-together-with-mir-210-3p-as-a-promising-biomarker-for-non-small-cell-lung-cancer-a-preliminary-study
#12
Weronika Świtlik, Michał Seweryn Karbownik, Michał Suwalski, Józef Kozak, Janusz Szemraj
BACKGROUND: Although an immense effort has been made to develop novel diagnostic methods and treatment strategies for non-small cell lung cancer (NSCLC), the survival rate of this disease has remained virtually unchanged. Small non-coding RNAs called microRNAs (miRNAs) have appeared to be very promising biomarkers of cancer including NSCLC. OBJECTIVE: We investigated the expression level of six miRNAs, and subsequently we evaluated their diagnostic ability and their clinical significance...
October 27, 2017: Cancer Biomarkers: Section A of Disease Markers
https://www.readbyqxmd.com/read/29100447/can-peripheral-blood-be-used-as-surrogate-in-detecting-epidermal-growth-factor-receptor-mutation-status-in-advanced-non-small-cell-lung-cancer-patients-a-meta-analysis
#13
Xiaowei Mao, Yujun Zhang, Fangfang Xie, Xiaoxuan Zheng, Jiayuan Sun
Background: Apply peripheral blood as a surrogate for detecting epidermal growth factor receptor mutation status in tumor, also called liquid biopsy, has been reported to be a feasible method in patients with advanced non-small lung cancer. But the diagnostic yield varies in different studies. Methods: A meta-analysis was carried out to evaluate the sensitivity and specificity of peripheral blood in detection epidermal growth factor receptor mutation status in advanced non-small lung cancer patients...
September 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/29084031/companion-and-complementary-diagnostics-focus-on-pd-l1-expression-assays-for-pd-1-pd-l1-checkpoint-inhibitors-in-nsclc
#14
Maria Hersom, Jan Trøst Jørgensen
Over the last couple of decades, molecular diagnostics have played an increasing role in drug development. Especially within oncology, more and more drugs are being developed together with a predictive biomarker assay using the drug-diagnostic co-development model. Not only do these assays support the development process but also the use of the drugs after regulatory approval as an important treatment decision tool. When these predictive biomarker assays are linked to a specific drug, they are called companion diagnostics...
October 27, 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/29078211/-personalized-therapy-of-lung-cancer-current-standard-and-future-challenges
#15
Richard Riedel, Jürgen Wolf
So called "personalized therapy" has revolutionized the care of non-small cell lung cancer (NSCLC). The discovery of more and more driver mutations in NSCLC has led to a molecular defined sub classification of lung cancer patients. For four driver mutations (EGFR(mut), ALK(transl), ROS1(transl), BRAF-V600(mut)) firstline approved drugs are available and became the treatment of choice. Further drugs are in clinical development or can be used as off-label treatment. The emergence of resistance under targeted therapy, the development of new drugs for further driver mutations and the broad implementation of molecular diagnostics for all lung cancer patients are future challenges...
November 2017: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/29069863/combination-of-platelet-count-and-lymphocyte-to-monocyte-ratio-is-a-prognostic-factor-in-patients-undergoing-surgery-for-non-small-cell-lung-cancer
#16
Wei Liu, Minwen Ha, Nanchang Yin
The aim of this study was to investigate the usefulness of a novel inflammation-based prognostic system, called COP-LMR (combination of platelet count and lymphocyte to monocyte ratio), for predicting postoperative survival of patients with non-small cell lung cancer (NSCLC). COP-LMR was calculated on the basis of the obtained data. Patients with both an elevated platelet count (PLT) (>30 × 104mm-3) and a low LMR (<3.6) were assigned a score of 2, and patients with one or none of the parameters were assigned a score of 1 or 0, respectively...
September 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/29066671/-landscape-of-lung-cancer-with-oligometastasis
#17
Yasushi Goto, Jun Sato
Lung cancer with a few to several metastases is so-called oligometastatic disease. Patient with recurrence only to limited site is also known as oligo-recurrence, and may be included as oligometastatic disease. From biological aspect, any existence of metastases is a sign of systemic disease. Due to the reports of long survival with only local treatment and without systemic disease in oligometastatic lung cancer, word of oligometastasis is used with fascinating expectation of cure to advanced lung cancer. Most of the previous reports are retrospective and no comprehensive data exists for selecting patient for local treatment to oligometastasis...
October 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29057240/emerging-uses-of-circulating-tumor-dna-in-advanced-stage-non-small-cell-lung-cancer
#18
REVIEW
Melina Marmarelis, Jeffrey C Thompson, Charu Aggarwal, Tracey L Evans, Erica Carpenter, Roger B Cohen, Corey J Langer, Joshua Bauml
Targeted therapies have dramatically changed the treatment paradigm for a select group of patients with non-small cell lung cancer (NSCLC) whose tumors harbor targetable genetic aberrations. Patients with such genetic changes enjoy excellent responses to tyrosine kinase inhibitors (TKIs), but resistance is nearly inevitable. Resistance to first line TKIs is heterogeneous and multifactorial-multiple resistance mechanisms have been reported, and different metastatic foci in the same patient may have distinct resistance mechanisms...
September 2017: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29024572/radiological-manifestations-of-immune-related-adverse-effects-observed-in-patients-with-melanoma-undergoing-immunotherapy
#19
Parveen Sidhu, Alexander M Menzies, Georgina Long, Matteo Carlino, Shirleen Lorens, Rony Kapoor
Immunotherapy drugs work by stimulating the patient's own immune system to recognize and destroy cancer cells. This subclass of drugs is increasingly administered to patients with advanced melanoma. They are also commonly incorporated into other cancer therapies such as non-small cell lung cancer, renal cancer, head and neck cancers and Hodgkin lymphoma. The most commonly administered immunotherapeutic agents in the treatment of melanoma include programmed cell death protein 1 (PD-1) inhibitors, cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitors and a subclass of cytokines...
October 11, 2017: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/28993508/personalized-sirna-nanoparticle-systemic-therapy-using-metastatic-lymph-node-specimens-obtained-with-ebus-tbna-in-lung-cancer
#20
Tatsuya Kato, Daiyoon Lee, Huang Huang, William Cruz-Munoz, Hideki Ujiie, Kosuke Fujino, Hironobu Wada, Priya Patel, Hsin-Pei Hu, Kentaro Hirohashi, Takahiro Nakajima, Masaaki Sato, Mitsuhito Kaji, Kichizo Kaga, Yoshiro Matsui, Juan Chen, Gang Zheng, Kazuhiro Yasufuku
Inhibiting specific gene expression with short interfering RNA (siRNA) provides a new therapeutic strategy to tackle many diseases at the molecular level. Recent strategies called high-density lipoprotein (HDL)-mimicking peptide-phospholipid nanoscaffold (HPPS) nanoparticles have been used to induce siRNAs-targeted delivery to scavenger receptor class B type I receptor (SCARB1) expressing cancer cells with high efficiency. Here, eight ideal therapeutic target genes were identified for advanced lung cancer throughout the screenings using endobronchial ultrasonography-guided transbronchial needle aspiration (EBUS-TBNA) and the establishment of a personalized siRNA-nanoparticle therapy...
October 9, 2017: Molecular Cancer Research: MCR
keyword
keyword
106365
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"